Skip to main content

Table 1 Characteristics of the included studies

From: Effect of intermittent Pringle maneuver on perioperative outcomes and long-term survival following liver resection in patients with hepatocellular carcinoma: a meta-analysis and systemic review

Study

Design

NOS score

Group

Occlusion time (min)

Type of resection Minor/Major

Sample size

Age

Gender M/F

Child–Pugh A/B

Cirrhosis Y/N

HBV/HCV

Tumor size

Tumor number S/M

AFP (ng/ml)

Differentiation W/Mo/P

Survival (months)

Xia [23]

R

8

IPM

50 (30–98)

131/93

224

48 (21–78)

173/51

141/83

169/55

209/NR

6.4 (2.8–20.2)

145/79

143(≥ 400)

NR

mDFS for all patients 26.1

2013

  

NPM

 

85/77

162

57 (18–79)

119/43

101/61

128/34

149/NR

5.9 (2.9–21.3)

122/40

93(≥ 400)

NR

 

Huang JW [22]

R

7

IPM

NR

374/338

712

56.1 ± 16.55

505/207

NR

518/194

543/59

8.6 ± 7.8

513/199

8176.3 ± 3211.5

NR

NR

2014

  

NPM

 

329/289

618

54.2 ± 22.1

473/145

NR

322/296

469/52

7.7 ± 5.1

433/185

6421.2 ± 5641.9

NR

NR

Huang ZP [21]

R

9

IPM

41.9 ± 12.3

0/158

158

48.5 ± 12.0

129/29

NR

NR

134/NR

NR

NR

NR

NR

NR

2014

  

NPM

 

0/200

200

50.4 ± 12.6

175/25

NR

NR

155/NR

NR

NR

NR

NR

NR

Hao [20]

R

8

IPM

31.5 ± 12.5

28/50

78

57.1

60/18

48/30

NR

63/NR

32 (≤ 5 cm) 46 (> 5 cm)

47/31

NR

51/27 (W + Mo/P)

OS 19.0 ± 4.2 DFS 14.2 ± 4.6

2016

  

NPM

 

25/35

60

53.6

48/12

40/20

NR

50/NR

26 (≤ 5 cm) 34 (> 5 cm)

39/21

NR

37/23

mOS 20.0 ± 3.8 mDFS 18.0 ± 4.8

Hao [19]

R

9

IPM

27.7 ± 7.3

42/71

113

51.7

76/37

74/39

NR

92 (HBV + HCV)

40 (≤ 5 cm) 73 (> 5 cm)

67/46

NR

78/35 (W + Mo/P)

mOS 46.3 mDFS 39.4

2017

  

NPM

 

25/27

52

55

37/15

35/17

NR

43 (HBV + HCV)

22 (≤ 5 cm) 30 (> 5 cm)

34/18

NR

32/20

mOS 52.9

mDFS 47.3

Famularo [18]

R

8

IPM

23 (14–30)

153/22

176

65.1 (58.2–72)

145/21

160/15

144/32

NR

119 (< 5 cm) 56 (≥ 5 cm)

133/42

21 (6–132)

NR

mOS 46.4 mDFS 26.7

2018

  

NPM

 

228/36

265

67.6 (59.2–73.9)

199/66

248/16

214/51

NR

199 (< 5 cm) 65 (≥ 5 cm)

210/54

18 (6–177)

NR

mOS 56.5 mDFS 24.9

Lee

RCT

 

IPM

45 (15–87)

51/37

88

58.0 (38.0–84.0)

75/13

88/0

53/25

66/12

3.9 (1.0–12.3)

64/24

28.0 (1.0–191,009.0)

10/73/5

NR

2019

  

NPM

 

54/34

88

60.5 (27.0–81.0)

75/13

88/0

50/28

70/3

3.5 (1.0–18.0)

68/20

25.0 (1.0–16,246.0)

5/78/5

NR

Wei [16]

R

9

IPM

50 (30–80)

59/49

108

51.45 ± 12.45

87/21

95/11

40/68

83/NR

NR

NR

55 (> 40)

NR

NR

2019

  

NPM

 

44/30

74

49.15 ± 11.10

63/11

65/6

26/48

64/NR

NR

NR

36 (> 40)

NR

NR

Galindo [15]

PSM

9

IPM

19.5 (5–78)

34/12

46

69 (49–85)

36/10

32/2

34/12

4/12

3.1 (0.6–14)

38/8

NR

NR

NR

2022

  

NPM

 

36/10

46

68 (19–86)

35/11

31/3

34/12

9/15

3.0 (0.3–9.5)

37/9

NR

NR

NR

  1. R retrospective study, RCT randomized controlled trial, PSM propensity score matched study, NOS Newcastle–Ottawa Scale, IPM intermittent Pringle maneuver, NPM non-Pringle maneuver, NR not reported, M male, F female, Y yes, N no, HBV hepatitis virus B, HCV hepatitis virus C, S solitary, M multiple, AFP alpha-fetoprotein, W well, Mo moderate, P poor, OS overall survival, DFS disease-free survival, mOS median overall survival, mDFS median overall survival